Pathologically Confirmed Cancer Refractory to Conventional Therapy
1 clinical trials · Condition
◉ Watch Pathologically Confirmed Cancer Refractory to Conventional Therapy
| Record | Firm | Date |
|---|---|---|
| Study of Allogeneic Blood-derived Natural Killer Cells to Evaluate Safety and Tolerability in Cancer Refractory to Conventional Therapy (NCT05990920) | NKGen Biotech, Inc. | 2023-08-23 |
Track Pathologically Confirmed Cancer Refractory to Conventional Therapy automatically
Every clearance here is in the API, with alerts when new ones post.